Literature DB >> 28647363

CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein.

Julia Obergasteiger1, Christa Überbacher1, Peter P Pramstaller2, Andrew A Hicks1, Corrado Corti3, Mattia Volta4.   

Abstract

The Ca2+-dependent activator protein for secretion 2 (CADPS2) is a member of the CAPS/CADPS protein family that plays crucial roles in synaptic vesicle dynamics. Genomic variability in the CADPS2 gene has been associated to autism spectrum disorders and Alzheimer's disease, both characterized by altered neurotransmission. Biological evidence also linked CADPS2 to Parkinson's disease (PD), as a disease-causing mutation in leucine-rich repeat kinase 2 (LRRK2) was reported to increase CADPS2 gene and protein expression. Furthermore, restoration of CADPS2 physiologic levels was able to provide neuroprotection in patient-derived neurons, consistent with the synaptic dysfunction postulated to underlie PD. However, little is known about the influence of PD-related proteins on transcriptional regulation of critical synaptic genes such as CADPS2. Here we aimed at investigating the transcriptional effects of LRRK2 and alpha-synuclein (aSyn) on CADPS2 gene expression, using a combination of in silico analyses and cell biology techniques. First, we identified a predicted promoter in the human CADPS2 genomic sequence, which we then utilized in a luciferase-based gene reporter assay. This approach enabled us to disclose a differential effect of high levels of LRRK2 and aSyn on CADPS2 promoter activity. Specifically, CADPS2 transcriptional activity was enhanced by high cellular levels of LRRK2 and reduced by overexpression of aSyn. Consistently, CADPS2 mRNA levels were diminished in aSyn overexpressing cells. Our results indicate that LRRK2 and aSyn participate in the dysregulation of CADPS2 by altering transcription and support the hypothesis that synaptic dysfunctions, through different mechanisms, might contribute to the neuronal defects of diseases such as PD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; CADPS2; Gene expression; LRRK2; Neuroblastoma cells; Parkinson's disease

Mesh:

Substances:

Year:  2017        PMID: 28647363     DOI: 10.1016/j.bbrc.2017.06.134

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions.

Authors:  Julia Obergasteiger; Giulia Frapporti; Giulia Lamonaca; Sara Pizzi; Anne Picard; Alexandros A Lavdas; Francesca Pischedda; Giovanni Piccoli; Sabine Hilfiker; Evy Lobbestael; Veerle Baekelandt; Andrew A Hicks; Corrado Corti; Peter P Pramstaller; Mattia Volta
Journal:  Cell Death Discov       Date:  2020-06-08

2.  An Alternative Exon of CAPS2 Influences Catecholamine Loading into LDCVs of Chromaffin Cells.

Authors:  Olga Ratai; Claudia Schirra; Elvin Rajabov; Irene Brunk; Gudrun Ahnert-Hilger; Praneeth Chitirala; Ute Becherer; David R Stevens; Jens Rettig
Journal:  J Neurosci       Date:  2018-11-02       Impact factor: 6.167

3.  Significant Changes in Plasma Alpha-Synuclein and Beta-Synuclein Levels in Male Children with Autism Spectrum Disorder.

Authors:  Wilaiwan Sriwimol; Pornprot Limprasert
Journal:  Biomed Res Int       Date:  2018-04-08       Impact factor: 3.411

4.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions.

Authors:  Julia Obergasteiger; Giulia Frapporti; Giulia Lamonaca; Sara Pizzi; Anne Picard; Alexandros A Lavdas; Francesca Pischedda; Giovanni Piccoli; Sabine Hilfiker; Evy Lobbestael; Veerle Baekelandt; Andrew A Hicks; Corrado Corti; Peter P Pramstaller; Mattia Volta
Journal:  Cell Death Discov       Date:  2020-06-08

5.  Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study.

Authors:  Kadalraja Raghavan; Vidyasagar Devaprasad Dedeepiya; Nobunao Ikewaki; Tohru Sonoda; Masaru Iwasaki; Senthilkumar Preethy; Samuel Jk Abraham
Journal:  BMJ Neurol Open       Date:  2022-01-18

6.  Complementary Transcriptomic and Proteomic Analysis in the Substantia Nigra of Parkinson's Disease.

Authors:  Bao-Hua Dong; Zhao-Qing Niu; Jing-Tao Zhang; Yi-Jing Zhou; Fan-Mei Meng; Ai-Qin Dong
Journal:  Dis Markers       Date:  2021-10-07       Impact factor: 3.434

Review 7.  Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.

Authors:  Ailyn Irvita Ravinther; Hemaniswarri Dewi Dewadas; Shi Ruo Tong; Chai Nien Foo; Yu-En Lin; Cheng-Ting Chien; Yang Mooi Lim
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.